Unknown PHASE4 INTERVENTIONAL 2-arm NCT04854083

Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes (MitoSema)

Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes - Effects on Glucose Metabolism, Prevention of Weight Regain and Peripheral Tissue Metabolic Activation

Sponsor: Kirsi Pietiläinen

Conditions Type2 Diabetes

Interventions Placebo Semaglutide, 1.34 mg/mL

Updated 5 times since 2021 Last updated: Mar 17, 2022 Started: Feb 17, 2022 Primary completion: Aug 31, 2025 Completion: Aug 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04854083, this PHASE4 trial focuses on Type2 Diabetes and remains ongoing. Sponsored by Kirsi Pietiläinen, it has been updated 5 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Oct 2025 — Present [monthly]

Unknown PHASE4

Status: Recruiting → Unknown
Sep 2024 — Oct 2025 [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Apr 2022 — Jul 2024 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
May 2021 — Apr 2022 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Kirsi Pietiläinen
Turku University Hospital
University of Helsinki

Data source: Helsinki University Central Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Helsinki, Finland